CAJ | 학술논문

三阴性乳腺癌( TNBC)是雌激素受体、孕激素受体以及人表皮生长因子受体均为阴性的乳腺癌。相对于其他乳腺癌亚型，其具有侵袭性强、恶性程度高、患者预后差、辅助治疗后复发转移率高等特点。 TNBC对化疗较为敏感，治疗仍以细胞毒性药物为主。近年来，随着肿瘤分子生物学研究的深入，分子靶向治疗成为近几年乳腺癌研究和关注的焦点。该文就TNBC的治疗进展作一综述。
삼음성유선암( TNBC)시자격소수체、잉격소수체이급인표피생장인자수체균위음성적유선암。상대우기타유선암아형，기구유침습성강、악성정도고、환자예후차、보조치료후복발전이솔고등특점。 TNBC대화료교위민감，치료잉이세포독성약물위주。근년래，수착종류분자생물학연구적심입，분자파향치료성위근궤년유선암연구화관주적초점。해문취TNBC적치료진전작일종술。
The estrogen receptor, progesterone receptor and human epidermal growth factor receptor of triple negative breast cancer (TNBC) are negative. Compared to other breast cancer subtypes,TNBC has strong invasiveness,high degree of malignancy and poor prognosis,with high recurrence rate after adjuvant therapy. TNBC is more sensitive to chemotherapy,and cytotoxic drugs are the main drugs. In recent years, with the increasing depth study of tumor molecular biology,molecular targeted therapy for breast cancer has become the focus,and here is to make a review of the treatment advances of TNBC.